Literature DB >> 30777499

Psychiatric hospitalization following antipsychotic medication cessation in first episode psychosis.

Joseph F Hayes1, David Pj Osborn1, Andreas Lundin2, Christina Dalman2.   

Abstract

BACKGROUND: There are questions about the risk-benefit balance of longer-term antipsychotic medication treatment following first episode psychosis, especially in relation to relapse because of dopamine supersensitivity following treatment cessation. AIM: The purpose of this study was to determine whether hospitalization rates in first episode psychosis patients are associated with length of initial oral antipsychotic medication exposure.
METHODS: We examined psychiatric hospitalization rates in patients experiencing first episode of psychosis from the total population of Sweden between 1 January 2007-31 December 2016 ( n=7043). We categorised patients by the length of first antipsychotic treatment (<6 months, 6 months to <1 year, 1 year to <2 years, 2 years to <5 years and ⩾5 years).
RESULTS: Compared to those treated for <6 months, individuals receiving oral antipsychotic medications for ⩾5 years had less than half the cumulative incidence of hospitalization at all times between 1-4 years after treatment cessation.
CONCLUSION: We found no evidence that hospitalization rates increased with increasing baseline antipsychotic exposure.

Entities:  

Keywords:  Relapse; antipsychotic medication; first episode psychosis; hospitalization

Mesh:

Substances:

Year:  2019        PMID: 30777499      PMCID: PMC7613091          DOI: 10.1177/0269881119827883

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.562


  7 in total

Review 1.  A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature.

Authors:  Joseph Zohar; Stephen Stahl; Hans-Jurgen Moller; Pierre Blier; David Kupfer; Shigeto Yamawaki; Hiroyuki Uchida; Michael Spedding; Guy M Goodwin; David Nutt
Journal:  Eur Neuropsychopharmacol       Date:  2015-09-07       Impact factor: 4.600

2.  What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia?

Authors:  Christoph U Correll; Jose M Rubio; John M Kane
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

3.  20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia.

Authors:  Jari Tiihonen; Antti Tanskanen; Heidi Taipale
Journal:  Am J Psychiatry       Date:  2018-04-06       Impact factor: 18.112

4.  Is there compelling evidence that schizophrenia long-term treatment guidelines should be changed?

Authors:  Stefan Leucht
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

Review 5.  The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia.

Authors:  Donald C Goff; Peter Falkai; W Wolfgang Fleischhacker; Ragy R Girgis; Rene M Kahn; Hiroyuki Uchida; Jingping Zhao; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2017-05-05       Impact factor: 18.112

Review 6.  Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?

Authors:  Robin M Murray; Diego Quattrone; Sridhar Natesan; Jim van Os; Merete Nordentoft; Oliver Howes; Marta Di Forti; David Taylor
Journal:  Br J Psychiatry       Date:  2016-11       Impact factor: 9.319

7.  Practical recommendations for reporting Fine-Gray model analyses for competing risk data.

Authors:  Peter C Austin; Jason P Fine
Journal:  Stat Med       Date:  2017-09-15       Impact factor: 2.373

  7 in total
  1 in total

1.  A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse.

Authors:  Mark Abie Horowitz; Sameer Jauhar; Sridhar Natesan; Robin M Murray; David Taylor
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 7.348

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.